Skip to main content

Table 6 Summary of subgroup analysis for incidence of VOD

From: Busulfan systemic exposure and its relationship with efficacy and safety in hematopoietic stem cell transplantation in children: a meta-analysis

Sub group

 

Cut-off value (μM*min/L)

RR (95% CI)

Number of studies

Number of participants in treatment group

Number of participants in control group

I2%

Administration route

IV Bu alone

≤1350 versus> 1350

0.378 (0.158,0.906)

3

106

30

0

 

≤1500 versus> 1500

0.485 (0.171,1.377)

3

129

17

0

IV Bu + oral Bu/oral Bu

≤1350 versus> 1350

0.363 (0.163, 0.805)

4

101

31

0

≤1500 versus> 1500

0.316 (0.087,1.145)

2

34

11

0

VOD prophylaxis

Yes

≤1350 versus> 1350

0.476 (0.120, 1.885)

1

42

15

NA

 

≤1500 versus> 1500

0.491 (0.109, 2.216)

1

56

11

NA

No

≤1350 versus> 1350

0.349 (0.182, 0.670)

6

165

46

0

 

≤1500 versus> 1500

0.380 (0.145, 0.994)

4

107

17

0

  1. CI Confidence interval, NA Not applicable, IV Intravenous